NRG Therapeutics expands team with CDO appointment

UK-based NRG Therapeutics has announced the expansion of its team with the appointment of Paul Thompson as chief development officer (CDO).

In his role at NRG, Mr Thompson will be project lead for NRG5051 which is on track to commence first-in-human studies in early 2026.

NRG5051 is an oral, CNS-penetrant small molecule inhibitor of the mitochondrial permeability transition pore (mPTP) acting via a novel mechanism of action (MoA). Inhibition of the mPTP has been shown to be profoundly neuroprotective and significantly reduces neuroinflammation in pre-clinical models of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), and Parkinson’s. He will also take responsibility for all non-clinical development functions within NRG.